Skip to main content
Log in

Sentinel Lymph Node Biopsy in Endometrial Cancer: a New Standard of Care?

  • Gynecologic Cancers (LA Cantrell, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Lymph node status is one of the most important factors in determining prognosis and the need for adjuvant treatment in endometrial cancer (EMCA). Unfortunately, full lymphadenectomy bears significant surgical and postoperative risks. The majority of patients with clinical stage I disease will not have metastatic disease; thus, a full lymphadenectomy only increases morbidity in this population of patients. The use of the sentinel lymph node (SLN) biopsy has emerged as an alternative to complete lymphadenectomy in EMCA. By removing the highest yield lymph nodes, the SLN biopsy has the same diagnostic ability as lymphadenectomy while minimizing morbidity. The sensitivity of sentinel lymph node identification with robotic fluorescence imaging for detecting metastatic endometrial and cervical cancer (FIRES) trial published this year is the largest prospective, multi-institution trial investigating the accuracy of the SLN biopsy for endometrial and cervical cancer. Results of this trial found an excellent sensitivity (97.2%) and false negative rate (3%) with the technique. The conclusions from the FIRES trial and those of a recent meta-analysis are that SLN biopsy has an acceptable diagnostic accuracy in detecting lymphatic metastases, and can replace lymphadenectomy for this diagnostic purpose. There remains controversy surrounding the SLN biopsy in high-risk disease and the use of adjuvant therapy in the setting of low volume disease detected with ultrastaging. Current data suggests that the technique is accurate in high-risk disease and that the increased detection of metastasis helps guide adjuvant therapy such that oncologic outcomes are likely not affected by forgoing a full lymphadenectomy. Further prospective study is needed to investigate the impact of low volume metastatic disease on oncologic outcomes and the need for adjuvant therapy in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cancer Stat Facts: Endometrial cancer. Retrieved May 1, 2017, from https://seer.cancer.gov/statfacts/html/corp.html.

  2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study Cancer. 1987;60(8 Suppl):2035–41.

    CAS  PubMed  Google Scholar 

  3. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(1):36–44.

    Article  CAS  Google Scholar 

  4. Agar N, Philippe AC, Bourdel N, Rabischong B, Canis M, Le Bouedec G, et al. Morbidity of pelvic lymphadenectomy and para-aortic lymphadenectomy in endometrial cancer. Bull Cancer. 2015;102(5):428–35.

    Article  PubMed  Google Scholar 

  5. Son JH, Kong TW, Kim SH, Paek J, Chang SJ, Lee EJ, et al. Prediction of lymph node metastasis in patients with apparent early endometrial cancer. Obstetrics & gynecology science. 2015;58(5):385–90.

    Article  Google Scholar 

  6. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2015;(9):Cd007585.

  7. Hareyama H, Hada K, Goto K, Watanabe S, Hakoyama M, Oku K, et al. Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015;25(4):751–7.

    Article  Google Scholar 

  8. Beesley VL, Rowlands IJ, Hayes SC, Janda M, O'Rourke P, Marquart L, et al. Incidence, risk factors and estimates of a woman’s risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncol. 2015;136(1):87–93.

    Article  PubMed  Google Scholar 

  9. Fotopoulou C, El-Balat A, du Bois A, Sehouli J, Harter P, Muallem MZ, et al. Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer. Arch Gynecol Obstet. 2015;292(6):1321–7.

    Article  CAS  PubMed  Google Scholar 

  10. Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107(8):1823–30.

    Article  PubMed  Google Scholar 

  11. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet (London, England). 2010;375(9721):1165–72.

    Article  Google Scholar 

  12. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (London, England). 2009;373(9658):125–36.

    Article  CAS  Google Scholar 

  13. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–16.

    Article  PubMed  Google Scholar 

  14. Sharma C, Deutsch I, Lewin SN, Burke WM, Qiao Y, Sun X, et al. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol. 2011;205(6):562.e1–9.

    Article  Google Scholar 

  15. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109(1):11–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lefringhouse JR, Elder JW, Baldwin LA, Miller RW, DeSimone, CP, van Nagell JR, Jr., et al. Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer. Gynecol Oncol. 2017.

  17. Cetinkaya K, Atalay F, Bacinoglu A, Dervisoglu H. To what extent is risk grouping method successful in deciding surgical staging in endometrial cancer? Tumori. 2016;102(4):422–5.

    Article  PubMed  Google Scholar 

  18. Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. The Lancet Oncology. 2017;18(3):384–92.

    Article  PubMed  Google Scholar 

  19. Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). The Lancet Oncology. 2011;12(5):469–76.

    Article  PubMed  Google Scholar 

  20. •• Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. American journal of obstetrics and gynecology. Am J Obstet Gynecol. 2017;216(5):459–476.e10. Large systematic review and meta-analysis of the liturature on the sentinel lymph node technique with all relevant liturature to date.

    Article  PubMed  Google Scholar 

  21. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(31):3786–91.

    Article  Google Scholar 

  22. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. The Lancet Oncology. 2007;8(10):881–8.

    Article  CAS  PubMed  Google Scholar 

  23. Touhami O, Trinh XB, Gregoire J, Sebastianelli A, Renaud MC, Grondin K, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol. 2015;138(1):41–5.

    Article  PubMed  Google Scholar 

  24. Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, et al. Survival of patients with serous uterine carcinoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2017.

  25. Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, et al. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2016;23(1):196–202.

    Article  PubMed  Google Scholar 

  26. Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol. 2016;140(3):394–9.

    Article  PubMed  Google Scholar 

  27. How J, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, et al. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecol Oncol. 2017;144(3):503–9.

    Article  PubMed  Google Scholar 

  28. Barlin JN, Khoury-Collado F, Kim CH, Leitao MM Jr, Chi DS, Sonoda Y, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125(3):531–5.

    Article  PubMed  Google Scholar 

  29. • Abu-Rustum NR. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. Journal of the National Comprehensive Cancer Network : JNCCN. 2014;12(2):288–97. Updated guidelines on the staging of endometrial cancer and sentinel lymph node biopsy.

    Article  PubMed  Google Scholar 

  30. Papadia A, Zapardiel I, Bussi B, Ghezzi F, Ceccaroni M, De Ponti E, et al. Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye. J Cancer Res Clin Oncol. 2017;143(3):475–80.

    Article  CAS  PubMed  Google Scholar 

  31. Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, et al. Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol. 2016;23(11):3749–56.

    Article  PubMed  Google Scholar 

  32. Holloway RW, Ahmad S, Kendrick JE, Bigsby GE, Brudie LA, Ghurani GB, et al. A prospective cohort study comparing colorimetric and fluorescent imaging for sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol. 2017.

  33. Buda A, Crivellaro C, Elisei F, Di Martino G, Guerra L, De Ponti E, et al. Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99m)Tc and/or blue dye. Ann Surg Oncol. 2016;23(7):2183–91.

    Article  PubMed  Google Scholar 

  34. Buda A, Bussi B, Di Martino G, Di Lorenzo P, Palazzi S, Grassi T, et al. Sentinel lymph node mapping with near-infrared fluorescent imaging using indocyanine green: a new tool for laparoscopic platform in patients with endometrial and cervical cancer. J Minim Invasive Gynecol. 2016;23(2):265–9.

    Article  PubMed  Google Scholar 

  35. Eriksson AG, Montovano M, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, et al. Impact of obesity on sentinel lymph node mapping in patients with newly diagnosed uterine cancer undergoing robotic surgery. Ann Surg Oncol. 2016;23(8):2522–8.

    Article  PubMed  Google Scholar 

  36. Rocha A, Dominguez AM, Lecuru F, Bourdel N. Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging—a systematic review. Eur J Obstet Gynecol Reprod Biol. 2016;206:213–9.

    Article  CAS  PubMed  Google Scholar 

  37. Papadia A, Imboden S, Siegenthaler F, Gasparri ML, Mohr S, Lanz S, et al. Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol. 2016;23(7):2206–11.

    Article  PubMed  PubMed Central  Google Scholar 

  38. •• Rossi EC, Jackson A, Ivanova A, Boggess JF. Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013;23(9):1704–11. Largest, prospective trial evaluating the accuracy of the SLN biopsy technique in endometrial cancer.

    Article  Google Scholar 

  39. Geppert B, Lonnerfors C, Bollino M, Arechvo A, Persson J. A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2017.

  40. Sahbai S, Taran FA, Fiz F, Staebler A, Becker S, Solomayer E, et al. Pericervical injection of 99mTc-Nanocolloid is superior to Peritumoral injection for sentinel lymph node detection of endometrial cancer in SPECT/CT. Clin Nucl Med. 2016;41(12):927–32.

    Article  PubMed  Google Scholar 

  41. Martinelli F, Ditto A, Bogani G, Signorelli M, Chiappa V, Lorusso D, et al. Laparoscopic sentinel node mapping in endometrial cancer after hysteroscopic injection of indocyanine green. J Minim Invasive Gynecol. 2017;24(1):89–93.

    Article  PubMed  Google Scholar 

  42. • Sinno AK, Peijnenburg E, Fader AN, Temkin SM, Stone R, Levinson K, et al. Reducing overtreatment: a comparison of lymph node assessment strategies for endometrial cancer. Gynecol Oncol. 2016;143(2):281–6. Modeling analysis used to compare three lymph node assessment strategies in low-risk patients.

    Article  PubMed  Google Scholar 

  43. Ehrisman J, Secord AA, Berchuck A, Lee PS, Di Santo N, Lopez-Acevedo M, et al. Performance of sentinel lymph node biopsy in high-risk endometrial cancer. Gynecologic oncology reports. 2016;17:69–71.

    Article  PubMed  PubMed Central  Google Scholar 

  44. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2010(1):Cd007585.

  45. Raimond E, Ballester M, Hudry D, Bendifallah S, Darai E, Graesslin O, et al. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol. 2014;133(3):506–11.

    Article  PubMed  Google Scholar 

  46. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. p. 347–76.

  47. Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2013;23(5):964–70.

    Article  Google Scholar 

  48. Holloway RW, Gupta S, Stavitzski NM, Zhu X, Takimoto EL, Gubbi A, et al. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol. 2016;141(2):206–10.

    Article  PubMed  Google Scholar 

  49. Sawicki S, Kobierski J, Liro M, Wojtylak S, Lass P, Wydra D. Micrometastases in sentinel lymph node in endometrial cancer patients. Ginekol Pol. 2015;86(4):262–7.

    Article  PubMed  Google Scholar 

  50. • St Clair CM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol. 2016;23(5):1653–9. Retrospective investigation evaluating treatment strategies and oncologic outcomes in patients with low-volume lymph node metastasis.

    Article  PubMed  Google Scholar 

  51. Mathevet P, Lecuru F. Effect of sentinel lymph-node biopsy alone on the morbidity of the surgical treatment of early cervical cancer: results from the prospective randomized study Senticol2. Presented at ASCO Annual Meeting, Chicago, 2015. J Clin Oncol. 2015;33(suppl; abstr 5521).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emma C. Rossi MD.

Ethics declarations

Conflict of Interest

Stephanie A. Sullivan and Emma C. Rossi declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sullivan, S.A., Rossi, E.C. Sentinel Lymph Node Biopsy in Endometrial Cancer: a New Standard of Care?. Curr. Treat. Options in Oncol. 18, 62 (2017). https://doi.org/10.1007/s11864-017-0503-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0503-z

Keywords

Navigation